Changes in exposure to tobacco-related harmful and potentially harmful constituents among adults who switched completely from smoking cigarettes to use of the JUUL2 system for six days

被引:0
作者
Goldenson, Nicholas I. [1 ]
Shiffman, Saul [2 ]
Oliveri, Douglas [1 ]
Liang, Qiwei [1 ]
Black, Ryan A. [1 ]
机构
[1] Juul Labs Inc, 1000 F St NW,Suite 800, Washington, DC 20004 USA
[2] Pinney Associates Inc, Pittsburgh, PA USA
关键词
Biomarker of exposure; cigarette; electronic nicotine delivery system; JUUL2; reduced exposure; tobacco harm reduction; LUNG-CANCER DEVELOPMENT; URINARY LEVELS; BIOMARKERS; RISK; METABOLITES; HEALTH;
D O I
10.1080/1354750X.2024.2448493
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Introduction Adults who switch from smoking cigarettes to use of electronic nicotine delivery systems (ENDS) may reduce their exposure to harmful and potentially harmful constituents (HPHCs). This study assessed changes in exposure to HPHCs, assessed via biomarkers of exposure (BOEs), among adults who switched to a new ENDS product. Methods Adults who smoke cigarettes (N = 89) were randomized to: (1) switch completely to using JUUL2 Virginia Tobacco (N = 24) or Polar Menthol (N = 24); (2) continue smoking usual brand (UB) cigarettes (N = 21); or (3) abstain from all tobacco/nicotine products (N = 20) for 6 d. Changes in exposure to nicotine and 11 other HPHCs from Baseline to Day 6 were compared among study groups. Results Changes in nicotine exposure did not significantly differ between JUUL2 and UB Cigarette groups (ps > 0.37). Among participants who switched completely to JUUL2 products, median percent reductions (Day 6-Baseline) in non-nicotine BOEs ranged from 65% to 94%, significantly greater than changes in the UB Cigarette group (ps < 0.001). None of the non-nicotine BOEs significantly differed between the JUUL2 groups and the Abstinence group (ps > 0.025). Conclusions This randomized study demonstrates that adults who switch completely from smoking cigarettes to use of JUUL2 ENDS products substantially reduce their exposure to HPHCs associated with smoking-related diseases.
引用
收藏
页码:77 / 87
页数:11
相关论文
共 54 条
  • [51] Applications of biomarkers of exposure and biological effects in users of new generation tobacco and nicotine products: Tentative proposals
    Yach, Derek
    Scherer, Gerhard
    [J]. DRUG TESTING AND ANALYSIS, 2023, 15 (10) : 1127 - 1132
  • [52] Urinary Tobacco Smoke-Constituent Biomarkers for Assessing Risk of Lung Cancer
    Yuan, Jian-Min
    Butler, Lesley M.
    Stepanov, Irina
    Hecht, Stephen S.
    [J]. CANCER RESEARCH, 2014, 74 (02) : 401 - 411
  • [53] Urinary Levels of Cigarette Smoke Constituent Metabolites Are Prospectively Associated with Lung Cancer Development in Smokers
    Yuan, Jian-Min
    Gao, Yu-Tang
    Murphy, Sharon E.
    Carmella, Steven G.
    Wang, Renwei
    Zhong, Yan
    Moy, Kristin A.
    Davis, Andrew B.
    Tao, Li
    Chen, Menglan
    Han, Shaomei
    Nelson, Heather H.
    Yu, Mimi C.
    Hecht, Stephen S.
    [J]. CANCER RESEARCH, 2011, 71 (21) : 6749 - 6757
  • [54] Urinary Levels of Tobacco-Specific Nitrosamine Metabolites in Relation to Lung Cancer Development in Two Prospective Cohorts of Cigarette Smokers
    Yuan, Jian-Min
    Koh, Woon-Puay
    Murphy, Sharon E.
    Fan, Yunhua
    Wang, Renwei
    Carmella, Steven G.
    Han, Shaomei
    Wickham, Katie
    Gao, Yu-Tang
    Yu, Mimi C.
    Hecht, Stephen S.
    [J]. CANCER RESEARCH, 2009, 69 (07) : 2990 - 2995